Cleo Diagnostics

Cleo Diagnostics Ltd (ASX: COV) – Trading Halt

Description

The securities of Cleo Diagnostics Ltd (‘COV’) will be placed in trading halt at the request of COV, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 7 November 2023 or when the announcement is released to the market.


Issued by

Sam Dorland
Adviser, Listings Compliance


Click here for the full ASX Release

This article includes content from CLEO Diagnostics, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

COV:AU
Cleo Diagnostics

Cleo Diagnostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Cleo Diagnostics

Cleo Diagnostics


Keep reading...Show less

Medtronic to announce financial results for its second quarter of fiscal year 2025

- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2025 on Tuesday, November 19, 2024 . A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's second quarter of fiscal year 2025, which ended on Friday, October 25, 2024 .

Medtronic will host a video webcast at 7:00 a.m. CST on November 19, 2024 , to discuss results for its second quarter of full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

CMS grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral renal denervation catheter

The Symplicity blood pressure procedure offers patients a new adjunct approach to lowering blood pressure

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral ™ renal denervation (RDN) catheter, used in the Symplicity ™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment, which will be effective for up to three years beginning January 1, 2025 aims to support patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
CardieX Limited (ASX:CDX)

CONNEQT Pulse Pre-orders Commence

Cardiex Limited (ASX: CDX) (the Company) is pleased to announce pre-orders for the CONNEQT Arterial Health Assessment, which comes complete with the CONNEQT Pulse vascular biometric monitor, have commenced in the USA.

Keep reading...Show less

Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call

Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024 financial results on Thursday, November 7, 2024, prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date : Thursday, November 7, 2024
Time : 8:30 a.m. ET
Telephone : Toll Free: 1-800-836-8184 or International 1-289-819-1350
Webcast   : www.knighttx.com or Webcast
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.
Replay : An archived replay will be available for 30 days at www.knighttx.com .

About Knight Therapeutics Inc.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cardiex Limited

Cardiex September 2024 Quarter Update

Cardiex Limited (ASX:CDX) (the “Company”) is pleased to report its activities during the September quarter 2024.
Keep reading...Show less

SPYRAL HTN-ON MED study shows significant, consistent, long-term blood pressure lowering effect at two years

Company commits to advancing clinical data for Symplicity™ with the SPYRAL Gemini clinical trial and expansion of the GSR-DEFINE clinical trial

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term data from its SPYRAL HTN-ON MED clinical trial that showed subjects who underwent radiofrequency renal denervation with the Symplicity™ Spyral renal denervation (RDN) system had significantly greater reductions in 24-hr ambulatory systolic blood pressure (ABPM), and office-based systolic blood pressure (OSBP) compared to sham patients at two years. The data were presented as a part of the 2024 Transcatheter Cardiovascular Therapeutics Conference (TCT).

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cleo Diagnostics

Cleo Diagnostics Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×